A new delivery route can be scientifically interesting without proving a fertility outcome. That is the key distinction in a 2025 intranasal kisspeptin study.
The researchers used kisspeptin-54
The randomized, double-blind, placebo-controlled crossover study tested kisspeptin-54 in 12 healthy men, 12 healthy women and 10 women with hypothalamic amenorrhoea. A crossover means participants attended separate visits for the comparisons, rather than serving in only one treatment group.
What happened to LH?
| Study group | Difference versus placebo in maximum LH increase |
|---|---|
| Healthy men | 3.1 IU/L; 95% CI 1.2–4.9 |
| Healthy women | 1.0 IU/L; 95% CI 0.4–1.7 |
| Hypothalamic amenorrhoea | 4.3 IU/L; 95% CI 2.7–6.0 |
These selected comparisons describe the mean maximum increase above baseline, compared with placebo. LH is luteinising hormone. No side effects or adverse events were encountered in the reported study.
Why a hormone rise is only one part of the story
A measurement can show that a pathway responded. It does not automatically show that every later step worked. A hormone response, ovulation and a pregnancy outcome are different questions and need their own evidence.
The crossover design is useful for comparing responses within participants. It still leaves the study tied to its particular population, material, route and observation period. A small study with no observed adverse events cannot settle long-term safety.
Do not swap the peptide names
Kisspeptin-10 and kisspeptin-54 are different molecular forms. A shared family name is a reason to compare them carefully, not a reason to assume the nasal results apply to either one.
For laboratory planning, write the complete peptide identity on the request and explain the intended assay. If a paper uses one form while a catalog lists another, resolve that difference before treating the paper as evidence for the material you plan to test.
Related NHD research material
The NHD Kisspeptin-10 product page identifies related laboratory catalog options. This paper studied kisspeptin-54, not the kisspeptin-10 catalog entry. For a material enquiry, specify the exact identity, quantity, planned assay and required analytical records. Published results do not validate an NHD batch.
Ask NHD about material options and available documents.
Original research
Mills et al., Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans; 2025. Sources checked 10 October 2026.
AI-assisted editorial review checked study numbers, wording and product links; this is not independent peer review. NHD catalog materials are for laboratory research, development and manufacturing, not human or veterinary use. A catalog material is not a clinical trial medicine or a tested finished formulation.
Sources & editorial method
AI-assisted writing
1 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
AI-assisted source and readability checks, not independent peer review.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
